Abstract | BACKGROUND: METHODS: A total of 17 patients from Fudan University Shanghai Cancer Center (FUSCC) with advanced clear cell RCC were enrolled. They were treated with sunitinib (50 mg/day; 2 weeks on and 1 weeks off) as first-line therapy. After progression of the disease, sintilimab (200 mg iv/q3w) in combination with pazopanib (800 mg/day) were used. After 6-8 cycles of immunotherapy, patients were treated with pazopanib only. Cox proportional hazards models was used to evaluate the risk factors. RESULTS: Three patients reached partial response (PR) after second-line treatment, while 12 patients remained stable. Two patients had progressive disease and 1 of them died due to disease progression. The median progression-free survival (PFS) for second-line therapy was 12.2 months. Cox analysis revealed that IMDC score (HR: 0.041, P=0.01) was the only factor that was correlated with progression free survival. CONCLUSIONS:
|
Authors | Xiaolin Lu, Weijie Gu, Guohai Shi, Dingwei Ye |
Journal | Translational andrology and urology
(Transl Androl Urol)
Vol. 10
Issue 5
Pg. 2078-2083
(May 2021)
ISSN: 2223-4691 [Print] China |
PMID | 34159088
(Publication Type: Journal Article)
|
Copyright | 2021 Translational Andrology and Urology. All rights reserved. |